Last week the largest gathering in the world on healthcare convened in San Francisco. The Alliance for Regenerative Medicine (ARM) held its annual “State of the Industry” talk that reviewed 2017 and previewed 2018. It was, without doubt, the most exciting such update since ARM began this briefing.

The briefing on 2017 showed not one, but three cell therapy approvals! Although these cell therapies are directed at cancer therapy, they are cell therapy and showed that the FDA is willing to fast-track really legitimate new cell products. Perhaps more exciting to us in the adult stem cell area is the recommendation by a European Medicines committee to approve the first adipose-derived stem cell therapy for human Crohn’s Disease! This is the same type of cell therapy product that VetStem is testing for approval in veterinary medicine. This would be a first in Europe for people!

The briefing also previewed 2018 with the prospect for more approvals and they stated they expect 40 new cell products in the next five years.

VetStem is proud to be in the forefront in bringing cell therapy into the hands of the practicing veterinarian and we are grateful to the many owners who have trusted VetStem to provide Regenerative Cell Therapy for arthritis and tendon and ligament injuries for their beloved animals.

You can watch the Cell & Gene Therapies State of the Industry Briefing here.